{
    "clinical_study": {
        "@rank": "78845", 
        "arm_group": [
            {
                "arm_group_label": "Arm I (low-calorie diet)", 
                "arm_group_type": "Experimental", 
                "description": "Patients eat a special low-calorie diet during 3 days prior to chemotherapy, during the 12 weeks of chemotherapy, and 2 days after chemotherapy.  Patients are provided with all meals and all food to be consumed and maintain a diary of the food consumed and appropriate amounts."
            }, 
            {
                "arm_group_label": "Arm II (normal diet)", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients eat a normal diet and receive dietary advice which may include consultation with a nutritionist. Patients maintain a diary of the food consumed and appropriate amounts."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized phase II trial studies how well a controlled low calorie diet works in\n      reducing side effects and increasing response to chemotherapy in patients with breast or\n      prostate cancer. Drugs used in chemotherapy work in different ways to stop the growth of\n      cancer cells, either by killing the cells or by stopping them from dividing. Eating a\n      special diet with low calories may reduce the side effects of chemotherapy and improve the\n      response to treatment"
        }, 
        "brief_title": "Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer", 
            "Hormone-resistant Prostate Cancer", 
            "Recurrent Prostate Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Prostatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To obtain preliminary estimates of the impact of a restricted diet on toxicity and\n      efficacy of chemotherapy for breast and prostate cancer.\n\n      II. To evaluate the compliance with a controlled diet intervention.\n\n      III. To investigate changes in plasma insulin, glucose, insulin-like growth factor 1 (IGF1)\n      and IGF binding protein (IGFBP) levels in subjects who consume a restricted diet compared to\n      controls.\n\n      OUTLINE:\n\n      Patients are randomized to 1 or 2 treatment arms.\n\n      ARM I: Patients eat a special low-calorie diet during 3 days prior to chemotherapy, during\n      the 12 weeks of chemotherapy, and 24 hours after chemotherapy. Patients are provided with\n      all meals and all food to be consumed and maintain a diary of the food consumed and\n      appropriate amounts.  Patients meet with the study dietician within 3 weeks of enrollment\n      and prior to, or on the day of, their first course of chemotherapy on study and at the start\n      of each subsequent course.\n\n      ARM II: Patients eat a normal diet and receive dietary advice which may include consultation\n      with a nutritionist. Patients maintain a diary of the food consumed and appropriate amounts."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed breast cancer for which chemotherapy with AC (doxorubicin\n             plus cyclophosphamide) is being utilized in the neoadjuvant or adjuvant setting OR\n             castration-resistant prostate adenocarcinoma for which Docetaxel will be administered\n\n          -  Body mass index (BMI) >= 18.5\n\n          -  Subjects do not need to have measurable or evaluable disease; chemotherapy may be\n             administered in the neoadjuvant, adjuvant, or metastatic setting\n\n          -  Prior therapy:\n\n               -  Breast cancer subjects may not have received prior chemotherapy, with the\n                  exception of curative-intent chemotherapy for a separate malignancy more than 3\n                  years ago\n\n               -  Prostate cancer subjects may have received prior treatment with metronomic\n                  cyclophosphamide as this is considered anti-angiogenic/immunomodulatory and not\n                  cytotoxic\n\n               -  Prostate cancer subjects may be receiving a 2nd course of docetaxel provided\n                  that ** The first course resulted in a PSA response (> 30% reduction in prostate\n                  specific antigen [PSA] and/or improvement in radiographic findings or pain) and\n                  the last dose was >= 9 months ago\n\n          -  Prior Radiotherapy is allowed, provided at least 2 weeks have elapsed from completion\n             of radiotherapy to initiation of protocol treatment\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n\n          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2x upper limit\n             of normal (ULN)\n\n          -  Absolute neutrophil count (ANC) > 1500\n\n          -  Platelets (plts) > 90,000\n\n          -  Premenopausal women must have a negative pregnancy test and must agree to use barrier\n             contraception throughout the study period\n\n        Exclusion Criteria:\n\n          -  Diabetes Mellitus\n\n          -  Peripheral Neuropathy >= grade 1\n\n          -  Prior therapy with inhibitors of IGF-1\n\n          -  Concurrent use of somatostatin\n\n          -  Significant food allergies which would make the subject unable to consume the food\n             provided (ex: shellfish, soy or egg allergy)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01802346", 
            "org_study_id": "0S-10-3", 
            "secondary_id": "NCI-2013-00414"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm I (low-calorie diet)", 
                "description": "Consume a low-calorie diet", 
                "intervention_name": "dietary intervention", 
                "intervention_type": "Dietary Supplement", 
                "other_name": [
                    "Dietary Modification", 
                    "intervention, dietary"
                ]
            }, 
            {
                "arm_group_label": "Arm II (normal diet)", 
                "description": "Receive dietary advice", 
                "intervention_name": "nutritional support", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "nutritional assessment", 
                    "nutritional care", 
                    "support, nutritional"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm I (low-calorie diet)", 
                    "Arm II (normal diet)"
                ], 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 27, 2014", 
        "location": {
            "contact": {
                "email": "kristy.watkins@med.usc.edu", 
                "last_name": "Kristy Watkins, R.N.", 
                "phone": "323-865-0452"
            }, 
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90033"
                }, 
                "name": "USC Norris Comprehensive Cancer Center"
            }, 
            "investigator": {
                "last_name": "Tanya B. Dorff", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Phase II Clinical Trial of a Controlled Diet Prior to Selected Chemotherapy Treatment in Breast and Prostate Cancer to Evaluate the Impact on Toxicity and Efficacy", 
        "overall_contact": {
            "email": "Yvette.Viverette@med.usc.edu", 
            "last_name": "Yvette Viverette, R.N.", 
            "phone": "323-865-0459"
        }, 
        "overall_official": {
            "affiliation": "University of Southern California", 
            "last_name": "Tanya Dorff", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Occurrence of Grade 2+ non-hematologic symptomatic toxicity (fatigue, nausea and vomiting, anorexia, neuropathy, mucositis, cystitis, stomatitis), evaluated according to Common Terminology Criteria for Adverse Events version 4.0. The two arms will be compared, in terms of the proportion of patients with the occurrence of one of these toxicities.", 
            "measure": "Rate of chemotherapy-related toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01802346"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Measured using a summary statistic which includes Response Evaluation Criteria In Solid Tumors (RECIST) response, PSA response for men without measurable disease, pathologic complete response and clinical response for breast cancer patients. This rate will be compared between patients on the restricted diet and controls.", 
            "measure": "Tumor response", 
            "safety_issue": "No", 
            "time_frame": "Up to 12 weeks"
        }, 
        "source": "University of Southern California", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Southern California", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}